$ELV

Penczek Ronald W sold $149K of ELV

Penczek Ronald W (CAO & Controller) sold 369 shares of Elevance Health, Inc. (ELV) at $403.16 ($0.15M total) on 2026-06-12.

Original reporting
SEC EDGAR · Penczek Ronald W
Published Jun 15, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ELV
Neutral
high confidence
Mentioned
$ELV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELVNeutralLow
01

Why it matters

This provides a fresh datapoint on insider behavior but does not include any operational, financial, or regulatory development for Elevance Health.

02

Market read

Traders may note insider selling, but the disclosure lacks a fundamental catalyst and is unlikely to drive sustained repricing on its own.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional filings or context, signal quality is limited.

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-15 (after the 2026-06-12 sale)

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Elevance Health, Inc.

Company-level read

Ticker impact

$ELVNeutralHigh confidence
Context

SEC Form 4 shows Elevance Health CAO & Controller Penczek sold 369 shares in an open-market transaction on 2026-06-12.

Expected impact

Low near-term impact; any reaction is likely muted unless part of a larger pattern.

Evidence & confidence

The filing is a Form 4 insider transaction with no stated earnings, guidance, or regulatory catalyst; it also notes no 10b5-1 plan, but the disclosed size is modest (about $149k).

Market effects

Minimal; single-company insider sale does not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted as less “scheduled” selling, but the transaction size is small and not tied to any new company event.

Key entities

  • Elevance Health, Inc.

    Subject of the SEC Form 4 insider transaction disclosure.

  • Ronald W. Penczek

    CAO & Controller who sold 369 shares in an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ELVMed

Cantor Fitzgerald keeps Elevance stock rating on Medicare concerns

Cantor Fitzgerald maintained an Overweight rating and $450 price target for Elevance Health (ELV) despite a decline in its 2027 Medicare Stars ratings. The firm expects pressure on the stock due to concerns around Medicare Advantage management. Elevance reaffirmed its 2026 earnings guidance, projecting at least $20.10 per diluted share. Analysts have mixed views, with Guggenheim raising its target to $455 and RBC lowering it to $424.

$CNCHigh

ACA fraud crackdown threatens health insurer profits in 2026

Vice President JD Vance announced 760,000 ACA enrollees were dropped due to fraud, with 400,000 under review. Insurers like Centene, Molina, Elevance, and UnitedHealth saw stock declines. Experts warn of squeezed margins in 2026-2027 due to a less healthy risk pool. Premium rates for 2027 are locked, and insurers may push for higher 2028 rates. Brokers, who drive 75% of sign-ups, face new restrictions and potential reputational damage.